Volume 8.08 | Mar 3

Mammary Cell News 8.08 March 3, 2016
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  MCN on Twitter
Breast Cancer: An Improved Animal Model Opens Up New Treatments
Scientists have developed an animal model for breast cancer that faithfully captures the disease. Tested on human breast tissue, this the most clinically realistic model for breast cancer to date. [Press release from École Polytechnique Fédérale de Lausanne discussing online publication in Cancer Cell] Press Release | Abstract | Graphical Abstract
Learn More: Standardized Tools for Cancer Research
PUBLICATIONS (Ranked by impact factor of the journal)

RUNX1 Prevents Estrogen-Mediated AXIN1 Suppression and Beta-Catenin Activation in ER-Positive Breast Cancer
By depleting mammary epithelial cells of RUNX1 in vivo and in vitro, researchers demonstrated combinatorial regulation of AXIN1 by RUNX1 and estrogen. [Nat Commun] Full Article

Non-Migratory Tumorigenic Intrinsic Cancer Stem Cells Ensure Breast Cancer Metastasis by Generation of CXCR4 Migrating Cancer Stem Cells
Scientists showed that unlike highly metastatic cancer stem cells (mCSCs) residing in the breast tumor disseminating/peripheral regions, tumorigenic intrinsic CSCs (iCSCs) populate the inner mass of the tumor and are non-migratory. However iCSCs, via paracrine signaling, induce conversion of non-stem cancer cells to CSCs that are identical to the previously reported mCSCs, and in contrast to iCSCs, express chemokine receptor, chemokine receptor 4 (CXCR4), which is crucial for their metastatic potential. [Oncogene] Abstract

The Acetyltransferase Tip60 Contributes to Mammary Tumorigenesis by Modulating DNA Repair
Scientists demonstrated that Tip60 controls homologous recombination (HR)-directed DNA repair, and that Tip60 levels correlate inversely with a gene expression signature associated with defective HR-directed DNA repair. In human breast cancer data sets, Tip60 mRNA was downregulated, with low Tip60 levels correlating with p53 mutations in basal-like breast cancers. [Cell Death Differ] Full Article

Histone Deacetylase Inhibition Reveals a Tumor-Suppressive Function of MYC-Regulated miRNA in Breast and Lung Carcinoma
Investigators report that histone deacetylase (HDAC) inhibition in human breast and lung carcinoma cells activates an apoptotic mechanism mediated by microRNA (miRNA) and induced by the oncogene MYC. [Cell Death Differ] Abstract

Inhibiting Notch Activity in Breast Cancer Stem Cells by Glucose Functionalized Nanoparticles Carrying γ-Secretase Inhibitors
Investigators demonstrated that enhanced Notch signaling in breast cancer promotes self-renewal of cancer stem cells that display high glycolytic activity and aggressive hormone-independent tumor growth in vivo. [Mol Ther] Abstract | Full Article

MicroRNA Expression Profiling Identifies Decreased Expression of miR-205 in Inflammatory Breast Cancer
Researchers performed microRNA expression profiling in inflammatory breast cancer in comparison with locally advanced noninflammatory breast cancer. [Mod Pathol] Abstract

Interaction with Pyruvate Kinase M2 Destabilizes Tristetraprolin by Proteasome Degradation and Regulates Cell Proliferation in Breast Cancer
The authors identified tristetraprolin, an AU-rich, element-binding protein that regulates mRNA stability, as a new binding partner of pyruvate kinase M2. [Sci Rep] Full Article

Growth of Human Breast Tissues from Patient Cells in 3D Hydrogel Scaffolds
The authors describe a three-dimensional (3D) culture system that stimulates the outgrowth of morphologically complex and hormone-responsive mammary tissues from primary human breast epithelial cells. [Breast Cancer Res] Full Article | Press Release

PKC Activation Sensitizes Basal-Like Breast Cancer Cell Lines to Smac Mimetics
Investigators showed that the protein kinase C (PKC) activator TPA together with the Smac mimetic LBW242 induces cell death in two basal breast cancer cell lines that are resistant to Smac mimetic as single agent. [Cell Death Discov] Full Article


Fulvestrant plus Palbociclib versus Fulvestrant plus Placebo for Treatment of Hormone-Receptor-Positive, HER2-Negative Metastatic Breast Cancer that Progressed on Previous Endocrine Therapy (PALOMA-3): Final Analysis of the Multicentre, Double-Blind, Phase III Randomized Controlled Trial
Fulvestrant plus palbociclib was associated with significant and consistent improvement in progression-free survival compared with fulvestrant plus placebo, irrespective of the degree of endocrine resistance, hormone-receptor expression level, and PIK3CA mutational status. [Lancet Oncol] Abstract | Press Release

Learn to Enumerate Mammospheres & Tumorspheres Cultured in MammoCult: Watch Procedure Now
Targeting the RB-E2F Pathway in Breast Cancer
Researchers discuss recent advances in understanding of the RB-E2F pathway in breast cancer. They also discuss the application of genome-wide genetic screening efforts to gain insight into synthetic lethal interactions of CDK4/6 inhibitors in breast cancer for the development of more effective combination therapies. [Oncogene] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
PharmaMar Initiates a Phase II Trial with Antitumor Drug PM184 in Advanced Breast Cancer
PharmaMar has announced the start of an open-label multi-center two-stage Phase II trial with the anti-tumor drug PM184. [PharmaMar] Press Release

Cynvenio Honors Triple Negative Breast Cancer Day with Clinical Trial Launch
Cynvenio Biosystems, Inc. launch a clinical trial for women with triple negative breast cancer using the company’s non-invasive liquid biopsy technology to monitor participants and identify early signs of metastasis. [Cynvenio Biosystems, Inc.] Press Release

FDA Approves New Indication for FASLODEX® (Fulvestrant)
AstraZeneca announced that the US Food and Drug Administration (FDA) has approved a new indication expanding the use of FASLODEX® to include use in combination with palbociclib. The combination use is for the treatment of women with hormone receptor-positive, human epidermal growth factor receptor 2 negative advanced or metastatic breast cancer whose cancer has progressed after endocrine therapy. [AstraZeneca] Press Release

From our sponsor:
Modify hPSC genomes and enhance the physiological relevance of your research.
Watch the webinar now.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW International Society for Cellular Therapy (ISCT) 2016
May 25-28, 2016
Singapore, Singapore

Visit our events page to see a complete list of events in the mammary cell community.
NEW Research Technician – Breast Cancer (Kings College London)

NEW Research Associate – Breast Cancer (University of Cambridge)

NEW Postdoctoral Fellowship – Breast Cancer Stem Cells (Fundación para la Investigación Biosanitaria de Andalucia Oriental)

NEW Postdoctoral Fellowship – Microenvironment of Breast Cancer (Icahn School of Medicine)

Postdoctoral Fellowship – Breast and Prostate Cancer Molecular Mechanisms (Feinberg School of Medicine)

Postdoctoral Fellowship – Epigenetic Reprogramming of Breast Cancer Stem Cells (University of Toronto)

Postdoctoral Fellowship – Various Projects in Cancer Biology (National University of Singapore)

Postdoctoral Fellowship – Genetic and Epigenetic Variability in Breast Cancer (The University of Tennessee Health Science Center)

Clinical Research Fellow – Breast Pathology (Institute of Cancer Research)

Lead Bioinformatician – Breast Cancer Research (Institute of Cancer Research)

Pathologist – Breast/Gastrointestinal/Genitourinary Cancer (Beth Israel Deaconess Medical Center)

Manager – Medical and Breast Imaging (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellowship – Breast Cancer Biology (Washington University School of Medicine)

Professorship – Clinical Breast Cancer Research (University of Leeds)

Clinical Pathways Associate – Cancer Therapeutics (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellowship – Breast Cancer Development (University of Pennsylvania)

Director Clinical Research – Medical Oncology (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mammary Cell News: Archives | Events | Contact Us